Published in Neoplasia on July 16, 2004
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J (2011) 1.63
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 1.45
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol (2015) 1.06
Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry (2010) 0.96
Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc (2007) 0.96
Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm (2011) 0.95
Targeting ECM Disrupts Cancer Progression. Front Oncol (2015) 0.92
Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 0.92
Efficient hepatic delivery of drugs: novel strategies and their significance. Biomed Res Int (2013) 0.85
Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells. J Drug Deliv (2013) 0.85
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems. J Drug Deliv (2012) 0.82
Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. Nanoscale (2013) 0.81
Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo. Oncotarget (2015) 0.80
Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale (2014) 0.80
Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan. Invest New Drugs (2009) 0.78
Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. Mol Ther Nucleic Acids (2016) 0.78
Induction of Cancer Cell Death by Hyaluronic Acid-Mediated Uptake of Cytochrome C. J Nanomed Nanotechnol (2015) 0.77
A review of the past, present, and future directions of neoplasia. Neoplasia (2005) 0.77
Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells. Oncotarget (2016) 0.77
Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors. Cancer Sci (2015) 0.77
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. Int J Cell Biol (2015) 0.76
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. Int J Nanomedicine (2016) 0.76
Chemoenzymatic synthesis of oligohyaluronan-lipid conjugates. Bioconjug Chem (2014) 0.75
Fluorescence study of freeze-drying as a method for support the interactions between hyaluronan and hydrophobic species. PLoS One (2017) 0.75
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A (1991) 4.85
Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med (2003) 3.93
Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 3.75
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet (2003) 3.58
Lymphocyte homing receptors. Cell (1986) 2.70
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest (2001) 1.81
Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci (1994) 1.58
Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release (2001) 1.54
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer (2002) 1.53
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release (2000) 1.50
The normal structure and function of CD44 and its role in neoplasia. Mol Pathol (1998) 1.44
Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 1.37
A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf (2001) 1.33
Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer (2004) 1.26
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res (2002) 1.18
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res (1991) 1.16
Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target (2002) 1.16
Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res (1992) 1.16
CD44 and the adhesion of neoplastic cells. Mol Pathol (1997) 1.12
Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res (2000) 1.04
Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol (2000) 1.03
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res (2000) 1.02
Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res (1996) 1.00
Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta (2003) 0.99
Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys (1994) 0.98
Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst (1994) 0.97
Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem (1995) 0.94
Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer (1999) 0.92
CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med (Berl) (1995) 0.88
Targeted therapies for the treatment of cancer. Am J Surg (2003) 0.86
Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch Biochem Biophys (2000) 0.85
Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharm Res (2001) 0.84
Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol (1997) 0.82
Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target (2002) 0.82
CD44 and hyaluronan binding by human myeloid cells. Leuk Lymphoma (1996) 0.81
Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys (1998) 0.80
Identification and characterization of CD44RC, a novel alternatively spliced soluble CD44 isoform that can potentiate the hyaluronan binding activity of cell surface CD44. Neoplasia (1999) 0.79
Bioadhesive, collagen-modified liposomes: molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers. Biochim Biophys Acta (1994) 0.77
Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carrier Syst (1995) 0.77
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer (2004) 1.26
Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials (2010) 1.04
Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta (2003) 0.99
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res (2004) 0.93
Fluoxetine and reversal of multidrug resistance. Cancer Lett (2005) 0.84
Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment. Int J Pharm (2009) 0.84
Hyaluronan-modified and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-inflammatory response. J Control Release (2011) 0.82
Insights into modeling streptozotocin-induced diabetes in ICR mice. Lab Anim (NY) (2009) 0.81
A color discriminating broad range cell staining technology for early detection of cell transformation. J Carcinog (2009) 0.81
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett (2008) 0.80
Cyclooxygenase inhibition by diclofenac formulated in bioadhesive carriers. Biochim Biophys Acta (2008) 0.79
Lipsome-formulated enzymes for organophosphate scavenging: butyrylcholinesterase and Demeton-S. Arch Biochem Biophys (2005) 0.78
A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI. J Control Release (2008) 0.77
Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency. Nanomedicine (2008) 0.76
Three-dimensional characterization of drug-encapsulating particles using STEM detector in FEG-SEM. Micron (2008) 0.75
Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization. Eur J Pharm Sci (2010) 0.75